LeonaBio, Inc. (NASDAQ:LONA)
| Market Cap | 15.85M-13.2% |
| Revenue (ttm) | 0 |
| Net Income | -141.46M-136.3% |
| EPS | -32.78-111.8% |
| Shares Out | 3.94M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 85,725 |
| Open | 4.47 |
| Previous Close | 4.47 |
| Day's Range | 3.96 - 4.52 |
| 52-Week Range | 2.21 - 11.91 |
| Beta | 1.92 |
| Analysts | Buy |
| Price Target | 17.50(+335.32%) |
| Earnings Date | Nov 12, 2026 |
About LONA
LeonaBio, Inc. operates as a biopharmaceutical firm engaged in clinical-stage development. Its core mission revolves around crafting small molecule therapies aimed at revitalizing neurological function and arresting the advancement of neurodegenerative conditions. The company's active development portfolio encompasses ATH-1105, an experimental therapy for amyotrophic lateral sclerosis (ALS) that is currently undergoing Phase 1 clinical assessment. Similarly, ATH-1020 is also in Phase 1 trials, targeting various neurodegenerative disorders. Furthermore, LeonaBio has an array of earlier-stage compounds in preclinical research. The company, which was originally established as Athira Pharma, Inc., rebranded itself as LeonaBio, Inc. in January 2026. Founded in 2011, its corporate headquarters are situated in Bothell, Washington.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
2 firms rating LONA in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Nov 12, 2026Earnings report
$LONA stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in LONA holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by LONA's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
LONA Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New LONA patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to LONA from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in LONA
| VTIVanguard Morningstar Total Stock Market ETF | $654.23K |
| SURISimplify Propel Opportunities ETF | $396.40K |
| VXFVanguard Extended Market ETF | $294.13K |
| IWCiShares Micro-Cap ETF | $87.42K |
| DFMCU.S. Micro Cap Portfolio ETF | $16.87K |
| DCORU.S. Core Equity 1 Portfolio ETF Class Shares | $16.25K |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from LONA’s recent data — informational, not investment advice